Brief: Autolus Therapeutics Announces FDA Approval Of Aucatzyl® (Obecabtagene Autoleucel – Obe-Cel) For Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-All)
08/11/2024 21:26
Nov 8 (Reuters) - Autolus Therapeutics PLC 6A3Ay.F :
* AUTOLUS THERAPEUTICS ANNOUNCES FDA APPROVAL OF AUCATZYL®
(OBECABTAGENE AUTOLEUCEL – OBE-CEL) FOR ADULTS WITH
RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R
B-ALL)
* AUTOLUS THERAPEUTICS: SAFETY OF AUCATZYL INCLUDES A BOXED
WARNING FOR CRS, NEUROLOGIC TOXICITIES & SECONDARY HEMATOLOGICAL
MALIGNANCIES
Source text: ID:nGNX6kVCDn
Further company coverage: 6A3Ay.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants